Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, and that is roughly 9.11 % above the existing share price of $76.07.
Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the first quarter of 2021.
The analysts priced targets range from a high of hundred one dolars to a low of $61.
From its newest earnings report, released on 09/30/2020, the company found a quarterly revenue of $67.06 billion and a net benefit of $3.25 billion. The company’s market cap is actually $99.57 billion.
According to TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with 4 stars on a 0 5 stars ranking scale, with an average return of 11.5 % as well as a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The Long or retail Term Care segment includes offering of prescription drugs and assortment of general merchandise.
The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products as well as similar services, which includes medical, pharmacy, dental, behavioural health, medical control capabilities. The Corporate segment involves in offering administrative services and management. The company was developed by Stanley P. Goldstein and Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.